THRB and metabolic dysfunction-associated steatohepatitis: Until to now, only Rezdiffra, a thyroid hormone receptor beta (THR‐β) agonist, has been approved by the Food and Drug Administration (FDA) for the treatment of MASH (also known as “NASH”).